SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Suppliers

Read more breaking news

 

 

Promising growth forecast for Swiss biotech firm Evolva

By Nicola Cottam , 11-Apr-2014

Promising growth forecast for Swiss biotech firm Evolva

Swiss-based biotech Evolva is on target to launch a raft of products over the next few years on the back of recent successes.

A combination of strategic partnerships and production cost-savings in 2013 generated a 24% increase in revenue for the Swiss firm Evolva to £8.7m, according to the company’s financial report to 13 December.

Approximately 90% of total revenue came from research and development (R&D) through partnerships with three global ingredients suppliers (IFF, Ajinomoto and Roquette). Evolva also benefited from licensing income from EV-077 diabetic product, which is out-licensed to Norwegian biopharmaceutical company Serodus, as well as revenue from several research projects funded by the EU and national institutions.

The company is best known for its fermentation-based approach to developing ingredients for the health, nutrition and pharmaceutical markets and has spent last year consolidating key partnerships, including with Cargill and International Flavours & Fragrances (IFF) to finalise the production and launch of natural sweetener stevia and vanilla fragrance vanillin respectively.

CEO Neil Goldsmith explained: “Growth was in line with guidance and almost completely driven by product partnerships. We expect our partnerships to continue to contribute the majority of revenue in the next few years but we will increasingly take control production and marketing of our products, in a similar was to resveratrol, as our infrastructure grows and new products developed, including saffron ingredients which are currently in development.”

The pre-production phase for vanillin was completed earlier this year and a commercial launch date should be announced in the second half of the year. Meanwhile, the Cargill/Evolva joint venture to develop fermentation-derived steviol glycosides entered the pilot phase at the end of 2013 with the first products expected to market by 2015/16. As part of the deal, Cargill agreed to make a CHF4.5m equity investment in Evolva, which could equate to US$7.5m in future returns for the biotech group.

Since acquiring natural antioxidant resveratrol from the stricken Fluxome Sciences in 2012, Evolva has managed to significantly reduce production costs and is preparing for an end of the year launch. Resveratrol originally launched in the US in 2010, but sales were low due to high production costs. It already has GRAS (“Generally Recognised As Safe”) status in the US and Novel Foods authorisation in the European Union for use in Dietary Supplements. Furthermore, a ruling in 2013 by the Japanese Ministry of Health, Labour and Welfare is expected to facilitate the approval process for the product in Japan.

“R&D development has focused on finding gene combinations in yeast cells to generate the highest production rates to reduce production costs and make end-products more competitive. Fundamentally, it’s about making more grammes per litre per day,” said Goldsmith.

Evolva predicts revenues will exceed CHF 10 million (2013: CHF 8.7 million) in 2014. Net cash outflow from operating and investing activities is forecast to increase to CHF16-18m, primarily driven by stevia and resveratrol.

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars